AR072013A1 - Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas - Google Patents

Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas

Info

Publication number
AR072013A1
AR072013A1 ARP090102028A ARP090102028A AR072013A1 AR 072013 A1 AR072013 A1 AR 072013A1 AR P090102028 A ARP090102028 A AR P090102028A AR P090102028 A ARP090102028 A AR P090102028A AR 072013 A1 AR072013 A1 AR 072013A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
unsubstituted
substituted
cycloalkyl
Prior art date
Application number
ARP090102028A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR072013A1 publication Critical patent/AR072013A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a sulfonamidas N-heteroc¡clicas aneladas con grupo de cabeza de oxadiazolona y a sus sales fisiologicamente aceptables y derivados fisiologicamente funcionales que muestran actividad agonista de PPARd o PPARd y PPARa. Los compuestos son adecuados para el tratamiento y/o prevencion de trastornos del metabolismo de  cidos grasos y trastornos de utilizacion de la glucosa as¡ como de trastornos en los que est  implicada la resistencia a la insulina y trastornos desmielinizantes y otros trastornos neurodegenerativos del sistema nervioso central y periferico. Reivindicacion 1: Compuesto de la formula (1) en la que Y es O, S, SO, SO2, alquileno C0-2-N(R10) o C(R3)(R4); R1 es H, halogeno, alquilo C1-8, alquileno C0-4-cicloalquilo C3-7, alquileno C0-4-heteroarilo C5-10, alquileno C0-4-O-alquilo C0-8 o alquileno C0-4-arilo C6-10, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R2 es H, alquilo C1-8, halogeno o alquileno C0-4-O-alquilo C0-8, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R3 es H, alquilo C1-8, alquileno C0-4-cicloalquilo C3-7, alquileno C0-4-arilo C6-10, alquileno C0-4-heteroarilo C5-10 o alquileno C0-4-N(R10)(R11), donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R4 es H, alquilo C1-8, alquileno C0-4-cicloalquilo C3-7, alquileno C0-4-arilo C6-10, alquileno C0-4-heteroarilo C5-10 o alquileno C0-4-N(R10)(R11), donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R3 y R4 junto con el  tomo de carbono que tienen forman un anillo cicloalquilo C3-7, donde un  tomo de carbono puede reemplazarse por un hetero tomo seleccionado entre el grupo que consiste en O, S o N; R5 es H, alquilo C1-8, alquileno C0-4-cicloalquilo C3-7, alquileno C0-4-arilo C6-10, alquileno C0-4-heteroarilo C5-10 o alquileno C0-4-N(R10)(R11), donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R6 es H, alquilo C1-8, alquileno C0-4-cicloalquilo C3-7, alquileno C0-4-arilo C6-10, alquileno C0-4-heteroarilo C5-10 o alquileno C0-4-N(R10)(R11), donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R5 y R6 junto con el  tomo de carbono que tienen forman un anillo cicloalquilo C3-7, donde un  tomo de carbono puede reemplazarse por un hetero tomo seleccionado entre el grupo que consiste en O, S o N; R7 es H, halogeno, alquilo C1-8 o alquileno C0-4-O-alquileno C0-4-H, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R8 es H, halogeno, alquilo C1-8 o alquileno C0-4-O-alquileno C0-4-H, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F, por lo que R8 solo est  unido a carbono; R9 es H, halogeno, alquilo C1-8, alquileno C0-4-cicloalquilo C3-7, alquileno C0-4-O-alquilo C0-8 o alquileno C0-4-arilo C6-10, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R10 es H, alquilo C1-8 o alquileno C0-4-O-alquilo C0-8, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; R11 es H, alquilo C1-8 o alquileno C0-4-O-alquilo C0-8, donde el alquilo y el alquileno est n sin sustituir o sustituidos de 1 a 3 veces con F; X1, X2, X3, X4 y X5 son independientemente N o CH; en todas sus formas estereoisomericas y mezclas en cualquier proporcion, y sus sales fisiologicamente aceptables y formas tautomericas.
ARP090102028A 2008-06-09 2009-06-05 Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas AR072013A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290572 2008-06-09

Publications (1)

Publication Number Publication Date
AR072013A1 true AR072013A1 (es) 2010-07-28

Family

ID=40219356

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102028A AR072013A1 (es) 2008-06-09 2009-06-05 Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas

Country Status (19)

Country Link
US (2) US8329725B2 (es)
EP (1) EP2288604B1 (es)
JP (1) JP2011523664A (es)
KR (1) KR20110023855A (es)
CN (1) CN102056921A (es)
AR (1) AR072013A1 (es)
AU (1) AU2009256982A1 (es)
BR (1) BRPI0914978A2 (es)
CA (1) CA2727373A1 (es)
CL (1) CL2009001365A1 (es)
IL (1) IL209805A0 (es)
MA (1) MA32323B1 (es)
MX (1) MX2010013264A (es)
NZ (1) NZ589694A (es)
RU (1) RU2010154279A (es)
TW (1) TW201011012A (es)
UY (1) UY31872A (es)
WO (1) WO2009149820A1 (es)
ZA (1) ZA201007679B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008049864A1 (en) * 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012064744A2 (en) * 2010-11-08 2012-05-18 Lycera Corporation Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6242868B2 (ja) 2012-05-08 2017-12-06 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物
WO2013169704A2 (en) 2012-05-08 2013-11-14 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095788A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016276947A1 (en) * 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
EP3368535B1 (en) 2015-10-27 2020-12-02 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
JP2018535958A (ja) 2015-10-27 2018-12-06 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用
US10344000B2 (en) 2015-10-27 2019-07-09 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002040445A1 (en) * 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
DE10222034A1 (de) 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
US20060258683A1 (en) 2003-04-07 2006-11-16 Liu Kevin Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE10335450A1 (de) 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
JP2007530703A (ja) 2004-04-01 2007-11-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
CN102089281A (zh) * 2008-07-14 2011-06-08 参天制药株式会社 具有氨基甲酰基、脲基及取代氧基的新型吲哚衍生物
JPWO2010090009A1 (ja) * 2009-02-05 2012-08-09 国立大学法人京都大学 インドリン誘導体
US8691810B2 (en) * 2010-05-12 2014-04-08 Abbvie Inc. Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases

Also Published As

Publication number Publication date
WO2009149820A1 (en) 2009-12-17
US8946212B2 (en) 2015-02-03
CL2009001365A1 (es) 2010-11-05
EP2288604A1 (en) 2011-03-02
BRPI0914978A2 (pt) 2015-10-27
CA2727373A1 (en) 2009-12-17
TW201011012A (en) 2010-03-16
MX2010013264A (es) 2011-02-25
MA32323B1 (fr) 2011-05-02
UY31872A (es) 2010-01-29
KR20110023855A (ko) 2011-03-08
CN102056921A (zh) 2011-05-11
US8329725B2 (en) 2012-12-11
RU2010154279A (ru) 2012-07-20
US20110207738A1 (en) 2011-08-25
NZ589694A (en) 2012-05-25
AU2009256982A1 (en) 2009-12-17
IL209805A0 (en) 2011-02-28
JP2011523664A (ja) 2011-08-18
ZA201007679B (en) 2011-07-27
US20120122853A1 (en) 2012-05-17
EP2288604B1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
AR072013A1 (es) Sulfonamidas n-heterociclicas aneladas con grupo de cabeza de oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas
AR072012A1 (es) Pirrolidin sulfonamidas aneladas con grupo de cabeza de oxadiazolona, producto farmaceutico que comprende el compuesto activo y una o mas sustancias activas, y procedimiento de preparacion del producto
AR064299A1 (es) Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos
AR072041A1 (es) Piridil-n-(1,3,4) -tiadiazol-2-il-benceno sulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos
AR072014A1 (es) Sulfonamidas con grupo de cabeza de heterociclo y oxadiazolona, procesos para su preparacion y su uso como sustancias farmaceuticas
UY33458A (es) Derivados de metoxifenilo heterocíclicamente sustituidos con un grupo oxo, procedimientos para su preparación y uso de los mismos como medicamentos
AR056203A1 (es) Derivados de fenil-[1,2,4]-oxadiazol-5-ona con grupo fenilo, un procedimiento para la preparacion de un producto farmaceutico y el uso de este en la profilaxis o tratamiento de trastornos del snc y del metabolismo de la glucosa y de los acidos grasos
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
UY33485A (es) Derivados de acido(2-ariloxiacetilamino)fenilpropionico, procedimientos para su preparacion y uso de los mismos como medicamentos.
UY33484A (es) Derivados de dioxido de 1,3-propano sustituidos por espirociclos, procedimientos de obtencion y uso medico
AR085872A1 (es) Derivados heterobiciclicos n-sustituidos utiles para combatir parasitos en plantas y/o animales, composiciones que los contienen y metodos para combatir dichas plagas
UY33483A (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento.
AR098912A1 (es) Inhibidores de syk
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
BR112014014909A2 (pt) agonistas de tgr5 não sistêmicos
AR066583A1 (es) Derivados de 3,3-espiroindolinona
PE20141205A1 (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores de bace1 y/o bace2
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
AR071925A1 (es) Malonamidas como antagonistas de orexina
AR070188A1 (es) Derivados de sulfonamidas sustituidas
UY33722A (es) Oxazolidinonas como moduladores de mglur5
AR081908A1 (es) N-heteroaril-espirolactama-bipirrolidinas sustituidas, preparacion y usos terapeuticos de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure